glp 1 cirrhosis Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Exploring the Potential of GLP-1

In patients with T2D in a phase 2 clinical trial, retatrutide (0.5 to 12 mg) significantly reduced body weight and HbA1c levels compared to placebo and 1.5 mg dulaglutide

GLP-1 = glucagon-like peptide-1

A 2022 systematic review in Obesity Reviews found that GLP-1 associated weight loss showed comparable or slightly better muscle preservation than diet-only approaches

Int J Evol Biol

Managing Weight and Metabolism During Pregnancy Planning and Conception Stopping GLP-1 medications does not mean weight management stops during pregnancy planning

The philosophy of Macrobiotics posits that the body possesses an innate intelligence